NEW YORK, November 7, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Zoetis Inc. (NYSE: ZTS), Biogen Idec Inc. (NASDAQ: BIIB), Tenet Healthcare Corp. (NYSE: THC) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7776-100free.
--
Medtronic, Inc. Research Reports
On November 4, 2014, Medtronic, Inc. (Medtronic) reported that IN.PACT Admiral drug-coated balloon for the treatment of peripheral artery disease in leg arteries above the knee has provided a consistently favorable treatment effect in patients with diabetes in a landmark study of the investigational medical device, which is under review by the U.S. Food and Drug Administration (FDA) for approval. The Company informed that this finding comes from a pre-specified subgroup analysis of patients with diabetes in the IN.PACT SFA Trial that was presented at the Vascular InterVentional Advances 2014 (VIVA 14) meeting during a late-breaking clinical trials session by Dr. Peter Schneider, Chief of vascular surgery at Kaiser Foundation Hospital in Honolulu on November 4, 2014. The full research reports on Medtronic are available to download free of charge at:
http://www.analystsreview.com/Nov-07-2014/MDT/report.pdf
--
Zoetis Inc. Research Reports
On November 4, 2014, Zoetis Inc. (Zoetis) reported its Q3 2014 and 9M 2014 financial results. The Company reported 9.7% YoY improvement in its Q3 2014 revenue to $1.21 billion, helped by 12.5% YoY growth in Livestock revenue to $790 million and 5.4% YoY growth in companion animal revenue to $408 million, which was partially offset by 14.3% YoY decline in contract manufacturing revenue to $12 million. Q3 2014 net income attributable to Zoetis came in at $166 million or $0.33 per diluted share, compared to net income of $131 million or $0.26 per diluted share in Q3 2013. The Company reported Q3 2014 adjusted diluted EPS of $0.41. On average, ten analysts polled by Thomson Reuters expected the Company to report EPS (excluding special items) of $0.37 on revenue of $1.16 billion for the quarter. The Company's 9M 2014 revenue improved 4.8% YoY to $3.5 billion, while net income attributable to Zoetis came in at $457 million, up 14.5% YoY. The Company expects its full-year 2014 revenue between $4.70 and $4.75 billion and diluted EPS in the range of $1.16 - $1.20. The full research reports on Zoetis are available to download free of charge at:
http://www.analystsreview.com/Nov-07-2014/ZTS/report.pdf
--
Biogen Idec Inc. Research Reports
On October 31, 2014, Biogen Idec Inc. (Biogen) and Swedish Orphan Biovitrum AB (publ) (Sobi) - collaborators in the development and commercialization of ELOCTATE/ELOCTA - announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application of ELOCTA™ (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A. The validation of the MAA initiates the EMA's review process. The Company informed that ELOCTATE is the first recombinant clotting factor VIII therapy with prolonged circulation to provide protection from bleeding episodes with the potential for an extended interval between prophylactic injections. Douglas E. Williams, Ph.D., Executive Vice President of Research and Development at Biogen, said, "The validation of ELOCTA's application by the EMA is an important step toward bringing this innovative treatment to people with hemophilia A in Europe." The full research reports on Biogen are available to download free of charge at:
http://www.analystsreview.com/Nov-07-2014/BIIB/report.pdf
--
Tenet Healthcare Corp. Research Reports
On November 3, 2014, Tenet Healthcare Corp. (Tenet Health) reported a staggering 73.5% YoY improvement in its Q3 2014 net operating revenues to $4.2 billion, led by 77.2% YoY improvement in Hospital Operations and other revenues to $4.0 billion. Q3 2014 net income attributable to Tenet Health common shareholders came in at $9 million or $0.09 per diluted share, compared to net income of $28 million or $0.27 per diluted share in Q3 2013. Analysts polled by Thomson Reuters expected the Company to report EPS (excluding special items) of $0.10 on revenue of $4.0 billion for the third quarter. The Company's 9M 2014 net operating revenues improved 68.3% YoY to $12.1 billion, while net loss attributable to Tenet Health common shareholders stood at $49 million, compared to a net loss of $110 million in 9M 2013. The Company expects its full-year 2014 EPS in the range of $1.26 - $1.78. The full research reports on Tenet Health are available to download free of charge at:
http://www.analystsreview.com/Nov-07-2014/THC/report.pdf
--
Aetna Inc. Research Reports
On November 4, 2014, Aetna Inc. (Aetna) announced that the Company's Executive Vice President and CFO Shawn M. Guertin will present at the upcoming Credit Suisse 2014 Healthcare Conference on November 12, 2014, in Phoenix. The Company informed that its presentation is scheduled to begin at noon ET. Further, the presentation will be available live on the Company's official website. The full research reports on Aetna are available to download free of charge at:
http://www.analystsreview.com/Nov-07-2014/AET/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
